metoclopramide has been researched along with aprepitant in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chang, G; Di, L; Huang, Y; Lin, Z; Liston, TE; Scott, DO; Troutman, MD; Umland, JP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ballatori, E; Del Favero, A; Roila, F | 1 |
| Bassam, A; Pikó, B | 1 |
| Gray, SE; Nagy, CK; Navari, RM | 1 |
| Brunetti, AE; Nardulli, P; Russano, M; Silvestris, N | 1 |
| Angelelli, L; Ballatori, E; Caserta, C; Cavanna, L; Ciuffreda, L; Colantonio, I; Fasola, G; Fatigoni, S; Fava, S; Ionta, MT; Licitra, L; Massidda, B; Mirabile, A; Palladino, MA; Roila, F; Ruggeri, B; Tocci, A; Zerilli, F | 1 |
| Boutelet, I; Boyer, HG; Cailleux, AF; Cauliez, B; Cherifi, S; Defortescu, G; Dubessy, C; Duparc, C; Gobet, F; Guiheneuf, C; Lefebvre, H; Lopez, AG; Louiset, E; Ménard, JF; Wils, J | 1 |
2 review(s) available for metoclopramide and aprepitant
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Treatment of tumor therapy-induced nausea and vomiting].
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Drug Therapy, Combination; Humans; Methylprednisolone; Metoclopramide; Morpholines; Nausea; Neoplasms; Ondansetron; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Vomiting | 2009 |
4 trial(s) available for metoclopramide and aprepitant
| Article | Year |
|---|---|
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Female; Humans; Isoquinolines; Male; Metoclopramide; Middle Aged; Morpholines; Nausea; Neoplasms; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2013 |
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benztropine; Camptothecin; Dexamethasone; Drug Combinations; Female; Fluorouracil; Haloperidol; Humans; Leucovorin; Male; Metoclopramide; Morpholines; Nausea; Organoplatinum Compounds; Pancreatic Neoplasms; Vomiting | 2013 |
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Isoquinolines; Italy; Male; Metoclopramide; Middle Aged; Morpholines; Nausea; Palonosetron; Quality of Life; Quinuclidines; Risk Factors; Time Factors; Treatment Outcome; Vomiting; Young Adult | 2015 |
The neuropeptide substance P regulates aldosterone secretion in human adrenals.
Topics: Adolescent; Adrenal Cortex; Adrenal Glands; Adult; Aldosterone; Aprepitant; Cells, Cultured; Humans; Hypoglycemia; Male; Metoclopramide; Mineralocorticoids; Neurokinin-1 Receptor Antagonists; Placebos; Proof of Concept Study; Prospective Studies; Receptors, Neurokinin-1; Substance P; Transaminases; Young Adult | 2020 |
5 other study(ies) available for metoclopramide and aprepitant
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Species independence in brain tissue binding using brain homogenates.
Topics: Animals; Brain; Dogs; Guinea Pigs; Humans; Macaca fascicularis; Mice; Rats; Species Specificity | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist.
Topics: Acetals; Antiemetics; Aprepitant; Cisplatin; Dexamethasone; Humans; Metoclopramide; Morpholines; Neurokinin-1 Receptor Antagonists; Research Design; Vomiting | 1999 |